Nurix Therapeutics/$NRIX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Ticker

$NRIX
Primary listing

Industry

Biotechnology

Employees

286

ISIN

US67080M1036

NRIX Metrics

BasicAdvanced
$1B
-
-$2.81
2.24
-

What the Analysts think about NRIX

Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.

Bulls say / Bears say

Nurix Therapeutics has established strategic partnerships with major pharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, which validate its technology platform and offer potential for milestone payments and royalties. (Investing.com)
The company's lead candidate, NX-5948, is progressing towards pivotal trials for chronic lymphocytic leukemia (CLL) in 2025, potentially leading to accelerated approval in certain patient populations. (Investing.com)
Analysts have set an average 12-month price target of $30.7 for Nurix Therapeutics, indicating significant upside potential from its current trading price. (Nasdaq)
Nurix Therapeutics reported a negative EBITDA of $186.4 million in the last twelve months, reflecting ongoing financial challenges typical of clinical-stage biopharmaceutical companies. (Investing.com)
The biotechnology sector is highly competitive, with other companies developing BTK degraders and inhibitors, such as BeiGene's BGB-16673, which has shown similar efficacy in early trials, potentially challenging Nurix's market position. (Investing.com)
Nurix's revenue is anticipated to climb by 16% per year during the coming three years, which is significantly lower than the industry prediction of 140% growth each year, potentially impacting its competitive standing. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

NRIX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NRIX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NRIX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs